U.S. markets close in 2 hours 58 minutes
  • S&P 500

    3,964.58
    +63.22 (+1.62%)
     
  • Dow 30

    31,881.98
    +620.08 (+1.98%)
     
  • Nasdaq

    11,490.35
    +135.74 (+1.20%)
     
  • Russell 2000

    1,793.60
    +20.33 (+1.15%)
     
  • Crude Oil

    109.90
    -0.38 (-0.34%)
     
  • Gold

    1,849.00
    +6.90 (+0.37%)
     
  • Silver

    21.73
    +0.06 (+0.26%)
     
  • EUR/USD

    1.0676
    +0.0114 (+1.08%)
     
  • 10-Yr Bond

    2.8570
    +0.0700 (+2.51%)
     
  • GBP/USD

    1.2566
    +0.0071 (+0.56%)
     
  • USD/JPY

    127.8430
    -0.0070 (-0.01%)
     
  • BTC-USD

    30,249.00
    +353.88 (+1.18%)
     
  • CMC Crypto 200

    679.15
    +4.27 (+0.63%)
     
  • FTSE 100

    7,513.44
    +123.46 (+1.67%)
     
  • Nikkei 225

    27,001.52
    +262.49 (+0.98%)
     

Cooper Companies: Q1 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Cooper Companies (NYSE:COO) fell 2.6% in after-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share rose 17.84% year over year to $3.17, which beat the estimate of $2.78.

Revenue of $680,500,000 up by 5.31% from the same period last year, which beat the estimate of $660,670,000.

Guidance

Cooper Companies Sees FY21 Adj. EPS $12.90-$13.10, Sales $2.8B-$2.845B

How To Listen To The Conference Call

Date: Mar 04, 2021

Time: 05:00 PM

View more earnings on COO

ET Webcast URL: https://edge.media-server.com/mmc/p/cca2nmf2

Technicals

52-week high: $396.86

52-week low: $236.68

Price action over last quarter: Up 7.48%

Company Overview

Cooper Companies operates two units: CooperVision and CooperSurgical. Accounting for approximately 75% of total sales, CooperVision is the the second- largest player in the oligopolistic contact lens market. Over 50% of CooperVision's sales are in international territories. The second unit, CooperSurgical, develops and manufactures diagnostic and surgical products for gynecologists and obstetricians, including the Paragard IUD, which Cooper acquired from Teva in 2017.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.